Pfizer
Compare Pfizer…Diversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
PfizerDiversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
| Program / Trial | Phase / Date | Outcome |
|---|---|---|
| Lotiglipron (PF-07081532) | Phase 2; 2022-2023 | Oral small-molecule GLP-1 RA; once-daily; advanced into Phase 2 obesity + T2D cohorts; June 2023 discontinuation due to dose-dependent liver enzyme elevations observed during the Phase 2 program (ALT >3x ULN in multiple subjects) |
| Danuglipron BID (PF-06882961) Phase 1 | Phase 1; 2019-2020 | Oral small-molecule GLP-1 RA; twice-daily formulation; dose-response demonstrated; supported Phase 2 advancement |
| Danuglipron BID Phase 2a (T2D) | Phase 2a; 2021-2022 | Dose-related HbA1c reduction in T2D cohort; supported advancement to obesity Phase 2b; GI tolerability flagged as the limiting factor early |
| Danuglipron BID Phase 2b (obesity, 32 weeks) | Phase 2b; Dec 2023 readout | Up to 12.9% placebo-adjusted weight loss at 32 weeks (top 200mg BID dose). 38.5% overall adverse-event-related discontinuation (31.6% gastrointestinal; ~60% in the top 200mg BID arm) due to nausea, vomiting, and diarrhea. No ALT elevations >5x ULN were observed in this trial. Pfizer chose to discontinue the BID formulation and pivot to a once-daily reformulation |
| Danuglipron QD Phase 1 (reformulation) | Phase 1; 2024-2025 | Once-daily extended-release reformulation; pharmacokinetic profile supported lower peak concentrations to improve GI tolerability; April 2025 discontinuation after a single subject experienced asymptomatic but clinically meaningful liver enzyme elevation, leading Pfizer to end the entire danuglipron program |
| Cumulative R&D spend (estimated) | 2018-2025 | Pfizer does not disclose program-level R&D; analyst estimates put cumulative danuglipron + lotiglipron development cost at ~$300-500M including Phase 2 trials, manufacturing scale-up work, and discontinued Phase 3 prep. The hepatotoxicity signal in two unrelated chemotypes raised concerns about a possible class-wide oral GLP-1 RA liver-safety question (later complicated by competitor LLY orforglipron + GPCR aleniglipron Phase 2 data, which did not replicate the signal) |
| Strategic response: Metsera acquisition | Nov 2025 | Pfizer completed its acquisition of Metsera (NY obesity biotech) on November 13, 2025 at $65.60/share (~$7.0B upfront) plus a CVR of up to $20.65/share (up to $86.25/share, ~$10B total), after a bidding contest with Novo Nordisk. Metsera's lead assets are injectable GLP-1 (MET-097i, entering Phase 3) and injectable amylin (MET-233i, Phase 1). The acquisition is Pfizer's re-entry into obesity and the replacement for the discontinued danuglipron program |
| Strategic response: Sciwind ecnoglutide partnership | Feb 2026 | Pfizer China obtained exclusive Mainland China commercialization rights to ecnoglutide (Sciwind's injectable cAMP-biased GLP-1, NMPA-approved for type 2 diabetes in January 2026), worth up to $495M, announced February 24, 2026; Sciwind remains the marketing authorization holder. Part of Pfizer's broader obesity/metabolic push alongside the Metsera acquisition |
| Editorial. What this means for Pfizer | Strategic context | Pfizer is now 5+ years behind LLY + NVO in the obesity market with no commercial-stage internal program. The Metsera assets are 4-6 years from a potential launch. The discontinuation history is a cautionary case study in oral GLP-1 RA development: two independent chemotypes from one company both produced liver-safety signals, while competitors (LLY orforglipron, GPCR aleniglipron) did not. The post-mortem question of whether the danuglipron + lotiglipron liver findings were idiosyncratic or class-related remains unresolved publicly |
| Asset / Mechanism | Phase / Stage | Strategic Positioning |
|---|---|---|
| MET-097i (injectable GLP-1 receptor agonist) | Phase 2 complete; entering Phase 3 | Weekly-and-monthly subcutaneous injectable GLP-1 RA; the lead Metsera asset and Pfizer's primary obesity re-entry vehicle; positioned vs NVO semaglutide + LLY tirzepatide, and as the backbone for combination with MET-233i |
| MET-233i (injectable amylin analog) | Phase 1 (monotherapy + combination) | Monthly subcutaneous injectable amylin analog; mechanistically complementary to GLP-1; developed as monotherapy and in combination with MET-097i; competes with NVO's amylin programs (cagrilintide, amycretin) |
| Oral + preclinical pipeline | Earlier-stage / preclinical | Metsera also carries earlier-stage oral GLP-1 and additional incretin/amylin candidates plus preclinical discovery programs; pipeline depth was part of the acquisition rationale |
| Deal economics (final, completed Nov 13, 2025) | Up to ~$10B | $65.60/share cash (~$7.0B enterprise value) upfront + up to $20.65/share CVR tied to three clinical and regulatory milestones (up to $86.25/share total). The final terms followed a bidding contest with Novo Nordisk that raised Pfizer's original September 22, 2025 offer |
| Sciwind ecnoglutide partnership (China) | Mainland China commercialization; Feb 2026 | Pfizer China obtained exclusive Mainland China commercialization rights to ecnoglutide (Sciwind's injectable cAMP-biased GLP-1, NMPA-approved for type 2 diabetes January 2026) in a deal worth up to $495M announced February 24, 2026; Sciwind remains the marketing authorization holder. Secondary to the Metsera asset base |
| Manufacturing requirements | Capacity build-out post-deal | Pfizer's internal obesity manufacturing capacity is minimal post-danuglipron; Metsera's Phase 3 scale-up and future commercial launch will require new injectable peptide manufacturing investment (analyst estimates ~$1-2B capex over 2026-2028) |
| Editorial. Why this matters | Strategic context | The Metsera assets put Pfizer back in the obesity race but at a delayed timeline versus LLY and NVO. Pfizer's ~$10B headline price reflects the scarcity of clinical-stage obesity assets available for acquisition and the intensity of the Novo Nordisk bidding contest. The marquee question is whether Pfizer can compress the development timeline via parallel Phase 2 + Phase 3 starts and a competitive injectable combination profile |
2021-Q2-2026-Q1
2021-Q2-2026-Q1
1993-2025
$PFE
Re-entered obesity through M&A after danuglipron failed. Acquired Metsera November 2025 for about $7.3B upfront plus up to $3.5B in contingent milestones (up to about $10B headline) for an oral and injectable GLP-1 pipeline. Sciwind partnership for ecnoglutide in China ($495M).